Comment in

• Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial.

  Daw S, Claviez A, Kurch L, Stoevesandt D, Attarbaschi A, Balwierz W, Beishuizen A, Cepelova M, Ceppi F, Fernandez-Teijeiro A, Fosså A, Georgi TW, Hjalgrim LL, Hraskova A, Leblanc T, Mascarin M, Pears J, Landman-Parker J, Prelog T, Klapper W, Ramsay A, Kluge R, Dieckmann K, Pelz T, Vordermark D, Körholz D, Hasenclever D, Mauz-Körholz C. Daw S, et al. JAMA Oncol. 2025 Mar 1;11(3):258-267. doi: 10.1001/jamaoncol.2024.5636. JAMA Oncol. 2025. PMID: 39745682 Clinical Trial.
• Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Nonrandomized Clinical Trial.

  Hoppe BS, Milgrom SA, Renfro LA, Wu Y, Schwartz CL, Constine LS, McCarten KM, Kelly KM, Hodgson D, Castellino SM, Keller FG. Hoppe BS, et al. JAMA Oncol. 2025 Mar 1;11(3):340-342. doi: 10.1001/jamaoncol.2024.5648. JAMA Oncol. 2025. PMID: 39745710
• Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults: A Nonrandomized Clinical Trial.

  Daw S, Cole PD, Hoppe BS, Hodgson D, Beishuizen A, Garnier N, Buffardi S, Mascarin M, Lissat A, Mauz-Körholz C, Krajewski J, Akyol A, Crowe R, Anderson B, Xu Y, Drachtman RA, Kelly KM, Leblanc T, Harker-Murray P. Daw S, et al. JAMA Oncol. 2025 Mar 1;11(3):249-257. doi: 10.1001/jamaoncol.2024.5627. JAMA Oncol. 2025. PMID: 39745739 Clinical Trial.